Global elimination of chronic hepatitis

Research output: Contribution to journalReview article

Abstract

Chronic hepatitis is a major public health challenge that can be eliminated. There has already been progress toward this goal, especially with the prevention of chronic hepatitis B by vaccination and reductions in the transmission of hepatitis C from transfusions and unsafe injections. There are also potentially potent interventions to detect and treat HCV and HBV infections. However, for the elimination targets to be reached by 2030, substantially more resources and additional innovations are needed to make these interventions widely available. The degree to which elimination of hepatitis is global or focused on select subpopulations will be directly related to the vigor of the international response.

Original languageEnglish (US)
Pages (from-to)2041-2050
Number of pages10
JournalNew England Journal of Medicine
Volume380
Issue number21
DOIs
StatePublished - May 23 2019

Fingerprint

Chronic Hepatitis B
Chronic Hepatitis
Hepatitis C
Hepatitis
Vaccination
Public Health
Injections
Infection

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Global elimination of chronic hepatitis. / Thomas, David L.

In: New England Journal of Medicine, Vol. 380, No. 21, 23.05.2019, p. 2041-2050.

Research output: Contribution to journalReview article

@article{ea634dcf2cc74d718871932c24a2cabc,
title = "Global elimination of chronic hepatitis",
abstract = "Chronic hepatitis is a major public health challenge that can be eliminated. There has already been progress toward this goal, especially with the prevention of chronic hepatitis B by vaccination and reductions in the transmission of hepatitis C from transfusions and unsafe injections. There are also potentially potent interventions to detect and treat HCV and HBV infections. However, for the elimination targets to be reached by 2030, substantially more resources and additional innovations are needed to make these interventions widely available. The degree to which elimination of hepatitis is global or focused on select subpopulations will be directly related to the vigor of the international response.",
author = "Thomas, {David L}",
year = "2019",
month = "5",
day = "23",
doi = "10.1056/NEJMra1810477",
language = "English (US)",
volume = "380",
pages = "2041--2050",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "21",

}

TY - JOUR

T1 - Global elimination of chronic hepatitis

AU - Thomas, David L

PY - 2019/5/23

Y1 - 2019/5/23

N2 - Chronic hepatitis is a major public health challenge that can be eliminated. There has already been progress toward this goal, especially with the prevention of chronic hepatitis B by vaccination and reductions in the transmission of hepatitis C from transfusions and unsafe injections. There are also potentially potent interventions to detect and treat HCV and HBV infections. However, for the elimination targets to be reached by 2030, substantially more resources and additional innovations are needed to make these interventions widely available. The degree to which elimination of hepatitis is global or focused on select subpopulations will be directly related to the vigor of the international response.

AB - Chronic hepatitis is a major public health challenge that can be eliminated. There has already been progress toward this goal, especially with the prevention of chronic hepatitis B by vaccination and reductions in the transmission of hepatitis C from transfusions and unsafe injections. There are also potentially potent interventions to detect and treat HCV and HBV infections. However, for the elimination targets to be reached by 2030, substantially more resources and additional innovations are needed to make these interventions widely available. The degree to which elimination of hepatitis is global or focused on select subpopulations will be directly related to the vigor of the international response.

UR - http://www.scopus.com/inward/record.url?scp=85066097979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066097979&partnerID=8YFLogxK

U2 - 10.1056/NEJMra1810477

DO - 10.1056/NEJMra1810477

M3 - Review article

C2 - 31116920

AN - SCOPUS:85066097979

VL - 380

SP - 2041

EP - 2050

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 21

ER -